Your browser doesn't support javascript.
loading
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity.
Calabrese, Cassandra; Kirchner, Elizabeth; Villa-Forte, Alexandra; Hajj-Ali, Rula A; Moss, Brandon P; Fernandez, James P; Calabrese, Leonard.
Affiliation
  • Calabrese C; Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
  • Kirchner E; Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
  • Villa-Forte A; Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
  • Hajj-Ali RA; Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
  • Moss BP; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA.
  • Fernandez JP; Department of Allergy and Clinical Immunology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Calabrese L; Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA calabrl@ccf.org.
RMD Open ; 8(2)2022 09.
Article in En | MEDLINE | ID: mdl-36123015
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunity, Humoral / Pre-Exposure Prophylaxis Limits: Humans Language: En Journal: RMD Open Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunity, Humoral / Pre-Exposure Prophylaxis Limits: Humans Language: En Journal: RMD Open Year: 2022 Document type: Article Affiliation country: Country of publication: